NCT04350255 is a NA clinical trial of Total hip arthroplasty in Prospective, sponsored by Sahlgrenska University Hospital.

Who is sponsoring NCT04350255?

NCT04350255 is sponsored by Sahlgrenska University Hospital.

What drugs are being tested in NCT04350255?

Interventions in NCT04350255: Total hip arthroplasty, Total hip arthroplasty.

What condition does NCT04350255 study?

NCT04350255 studies Prospective.

Is NCT04350255 still recruiting?

NCT04350255 is currently recruiting now. Last updated 4 October 2022.

Last reviewed 2022-10-04 · How we verify

NCT04350255

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Register Based Prospective Study During Implementation of a New Cup

Recruiting now NA Last updated 4 October 2022

What this trial tests

NA trial testing Total hip arthroplasty in Prospective in 500 participants. Currently enrolling.

Timeline

1 August 2020

Primary endpoint
1 December 2024

1 August 2030

Quick facts

Lead sponsor	Sahlgrenska University Hospital
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	500
Start date	1 August 2020
Primary completion	1 December 2024
Estimated completion	1 August 2030
Sites	1 location across Sweden

Drugs / interventions tested

Total hip arthroplasty
Total hip arthroplasty

Conditions studied

Prospective — all drugs for Prospective →

Sponsor

Sahlgrenska University Hospital

Who can join

Adults 30 to 75, any sex, with Prospective. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In a prospective register-based study, we aim to evaluate the implant survival, clinical outcomes and X-ray findings by following a cohort of patients operated with the Trident II cup.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Total hip arthroplasty

Trials testing the same drug.

NCT06959498 — Long-term Survival of THA After Pelvic and/or Femoral Osteotomy · not yet recruiting
NCT06263569 — Effectiveness of Total Hip Arthroplasty for Patients With Osteoarthritis, a Target Trial Emulation Study · completed
NCT05647629 — Observational Study of the Development of Low Back Pain After Total Hip Arthroplasty. · recruiting
NCT04348968 — Maxera Large Cups - Canada · terminated
NCT04834492 — The Results of Total Hip Arthroplasty in Crowe Type 4 Hips. · completed

Other Sahlgrenska University Hospital trials

Trials by the same sponsor.

NCT07491094 — Repeated Examinations for Typing Pulmonary Embolism · recruiting
NCT07524608 — Implementing an Evidence-based, Standardized Care Bundle Targeting Register Nurses and Anaesthesiologists, to Enhance Pa · not yet recruiting
NCT07498959 — Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer · NA · recruiting
NCT06896578 — Latitude - Lateral Lymph Node Attitude Study · NA · not yet recruiting
NCT07035600 — Walking and Sitting Difficulties After Rectal Cancer Surgery · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04350255 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sahlgrenska University Hospital
Last refreshed: 4 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04350255.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing